BioNTech Results Presentation Deck

2022 Strategic Priorities ● ● Continue COVID-19 Vaccine Leadership 9 0-0 Label & geographic expansion Next-generation vaccines Innovations for pandemic preparedness ● ● ● Execute in Oncology First randomized Phase 2 readout Prepare for registrational trials POC data for CAR-T cell therapy ● POC, proof of concept; FIH, first-in-human; HSV 2, herpes simplex virus type 2 ● Expand in Infectious Disease Initiate 4 FIH vaccine trials: Shingles HSV 2 Tuberculosis Malaria ● ● ● ● 10+ additional mRNA vaccine programs Precision antibacterials Advance into New Therapeutic Areas ● ● ● III Autoimmune disease Regenerative medicine. Cardiovascular disease Invest in Foundation to Enable Accelerated Innovation and Expansion Digital & Al Capabilities | Technologies | Development Team | Manufacturing | Global Footprint BIONTECH

View entire presentation